Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Executive Summary
It looks like the end for Latruvo after a late-stage trial in soft tissue sarcoma patients did not confirm the overall survival benefit seen in the Phase II study that saw the Lilly drug get a speedy approval from the FDA and the EMA in 2016.
You may also be interested in...
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
What Late-Breakers To Look Out For At ASCO 2019
Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.